Go Pro
→ First Look: Elon’s “Starphone” (From Stansberry Research) (Ad)tc pixel Free STOK Stock Alerts

Stoke Therapeutics (STOK) Competitors

Stoke Therapeutics logo
$25.62 -0.39 (-1.50%)
Closing price 04:00 PM Eastern
Extended Trading
$25.62 0.00 (0.00%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

STOK vs. ALKS, RYTM, CGON, ORKA, and KNSA

Should you buy Stoke Therapeutics stock or one of its competitors? Stoke Therapeutics's main competitors and comparable companies include Alkermes (ALKS), Rhythm Pharmaceuticals (RYTM), CG Oncology (CGON), Oruka Therapeutics (ORKA), and Kiniksa Pharmaceuticals International (KNSA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Stoke Therapeutics compare to Alkermes?

Stoke Therapeutics (NASDAQ:STOK) and Alkermes (NASDAQ:ALKS) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

95.2% of Alkermes shares are held by institutional investors. 9.6% of Stoke Therapeutics shares are held by insiders. Comparatively, 4.6% of Alkermes shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Stoke Therapeutics presently has a consensus target price of $44.25, indicating a potential upside of 70.15%. Alkermes has a consensus target price of $54.47, indicating a potential upside of 30.56%. Given Stoke Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Stoke Therapeutics is more favorable than Alkermes.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Stoke Therapeutics
1 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.82
Alkermes
1 Sell rating(s)
5 Hold rating(s)
11 Buy rating(s)
2 Strong Buy rating(s)
2.74

In the previous week, Alkermes had 2 more articles in the media than Stoke Therapeutics. MarketBeat recorded 4 mentions for Alkermes and 2 mentions for Stoke Therapeutics. Stoke Therapeutics' average media sentiment score of 0.86 beat Alkermes' score of 0.82 indicating that Stoke Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Stoke Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Alkermes
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Alkermes has a net margin of 3.96% compared to Stoke Therapeutics' net margin of -753.60%. Alkermes' return on equity of 4.15% beat Stoke Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Stoke Therapeutics-753.60% -59.36% -51.46%
Alkermes 3.96%4.15%2.19%

Alkermes has higher revenue and earnings than Stoke Therapeutics. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Stoke Therapeutics$184.42M9.10-$6.89M-$3.34N/A
Alkermes$1.48B4.74$241.66M$0.38109.79

Stoke Therapeutics has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market. Comparatively, Alkermes has a beta of 0.32, suggesting that its share price is 68% less volatile than the broader market.

Summary

Alkermes beats Stoke Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Stoke Therapeutics compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Stoke Therapeutics (NASDAQ:STOK) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk.

Rhythm Pharmaceuticals currently has a consensus target price of $140.67, suggesting a potential upside of 50.40%. Stoke Therapeutics has a consensus target price of $44.25, suggesting a potential upside of 70.15%. Given Stoke Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Stoke Therapeutics is more favorable than Rhythm Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rhythm Pharmaceuticals
1 Sell rating(s)
3 Hold rating(s)
17 Buy rating(s)
0 Strong Buy rating(s)
2.76
Stoke Therapeutics
1 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.82

Rhythm Pharmaceuticals has a beta of 2.01, meaning that its share price is 101% more volatile than the broader market. Comparatively, Stoke Therapeutics has a beta of 1.26, meaning that its share price is 26% more volatile than the broader market.

Stoke Therapeutics has lower revenue, but higher earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rhythm Pharmaceuticals$189.76M33.78-$196.54M-$3.11N/A
Stoke Therapeutics$184.42M9.10-$6.89M-$3.34N/A

In the previous week, Rhythm Pharmaceuticals had 2 more articles in the media than Stoke Therapeutics. MarketBeat recorded 4 mentions for Rhythm Pharmaceuticals and 2 mentions for Stoke Therapeutics. Stoke Therapeutics' average media sentiment score of 0.86 beat Rhythm Pharmaceuticals' score of 0.26 indicating that Stoke Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Rhythm Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Stoke Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Rhythm Pharmaceuticals has a net margin of -85.59% compared to Stoke Therapeutics' net margin of -753.60%. Stoke Therapeutics' return on equity of -59.36% beat Rhythm Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Rhythm Pharmaceuticals-85.59% -159.87% -44.00%
Stoke Therapeutics -753.60%-59.36%-51.46%

Summary

Rhythm Pharmaceuticals beats Stoke Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Stoke Therapeutics compare to CG Oncology?

CG Oncology (NASDAQ:CGON) and Stoke Therapeutics (NASDAQ:STOK) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, media sentiment, risk, analyst recommendations, profitability and institutional ownership.

CG Oncology presently has a consensus price target of $87.78, suggesting a potential upside of 29.41%. Stoke Therapeutics has a consensus price target of $44.25, suggesting a potential upside of 70.15%. Given Stoke Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Stoke Therapeutics is more favorable than CG Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CG Oncology
1 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.73
Stoke Therapeutics
1 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.82

Stoke Therapeutics has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CG Oncology$4.04M1,488.23-$160.99M-$2.69N/A
Stoke Therapeutics$184.42M9.10-$6.89M-$3.34N/A

CG Oncology has a beta of 0.28, suggesting that its stock price is 72% less volatile than the broader market. Comparatively, Stoke Therapeutics has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market.

In the previous week, Stoke Therapeutics had 2 more articles in the media than CG Oncology. MarketBeat recorded 2 mentions for Stoke Therapeutics and 0 mentions for CG Oncology. Stoke Therapeutics' average media sentiment score of 0.86 beat CG Oncology's score of 0.00 indicating that Stoke Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
CG Oncology Neutral
Stoke Therapeutics Positive

Stoke Therapeutics has a net margin of -753.60% compared to CG Oncology's net margin of -3,602.68%. CG Oncology's return on equity of -25.20% beat Stoke Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CG Oncology-3,602.68% -25.20% -23.98%
Stoke Therapeutics -753.60%-59.36%-51.46%

26.6% of CG Oncology shares are owned by institutional investors. 4.8% of CG Oncology shares are owned by company insiders. Comparatively, 9.6% of Stoke Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Stoke Therapeutics beats CG Oncology on 11 of the 16 factors compared between the two stocks.

How does Stoke Therapeutics compare to Oruka Therapeutics?

Oruka Therapeutics (NASDAQ:ORKA) and Stoke Therapeutics (NASDAQ:STOK) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, media sentiment, valuation, profitability and analyst recommendations.

Oruka Therapeutics has a net margin of 0.00% compared to Stoke Therapeutics' net margin of -753.60%. Oruka Therapeutics' return on equity of -21.65% beat Stoke Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Oruka TherapeuticsN/A -21.65% -20.88%
Stoke Therapeutics -753.60%-59.36%-51.46%

56.4% of Oruka Therapeutics shares are held by institutional investors. 23.5% of Oruka Therapeutics shares are held by insiders. Comparatively, 9.6% of Stoke Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Oruka Therapeutics has a beta of -0.37, suggesting that its share price is 137% less volatile than the broader market. Comparatively, Stoke Therapeutics has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market.

Oruka Therapeutics presently has a consensus target price of $128.91, indicating a potential upside of 52.99%. Stoke Therapeutics has a consensus target price of $44.25, indicating a potential upside of 70.15%. Given Stoke Therapeutics' higher probable upside, analysts clearly believe Stoke Therapeutics is more favorable than Oruka Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oruka Therapeutics
1 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.82
Stoke Therapeutics
1 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.82

Stoke Therapeutics has higher revenue and earnings than Oruka Therapeutics. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oruka TherapeuticsN/AN/A-$105.43M-$2.03N/A
Stoke Therapeutics$184.42M9.10-$6.89M-$3.34N/A

In the previous week, Oruka Therapeutics and Oruka Therapeutics both had 2 articles in the media. Stoke Therapeutics' average media sentiment score of 0.86 beat Oruka Therapeutics' score of 0.00 indicating that Stoke Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oruka Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Stoke Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Oruka Therapeutics and Stoke Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Stoke Therapeutics compare to Kiniksa Pharmaceuticals International?

Stoke Therapeutics (NASDAQ:STOK) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

In the previous week, Kiniksa Pharmaceuticals International had 2 more articles in the media than Stoke Therapeutics. MarketBeat recorded 4 mentions for Kiniksa Pharmaceuticals International and 2 mentions for Stoke Therapeutics. Stoke Therapeutics' average media sentiment score of 0.86 beat Kiniksa Pharmaceuticals International's score of 0.66 indicating that Stoke Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Stoke Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Kiniksa Pharmaceuticals International
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Stoke Therapeutics presently has a consensus target price of $44.25, indicating a potential upside of 70.15%. Kiniksa Pharmaceuticals International has a consensus target price of $93.14, indicating a potential upside of 23.16%. Given Stoke Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Stoke Therapeutics is more favorable than Kiniksa Pharmaceuticals International.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Stoke Therapeutics
1 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.82
Kiniksa Pharmaceuticals International
0 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.78

Kiniksa Pharmaceuticals International has a net margin of 9.59% compared to Stoke Therapeutics' net margin of -753.60%. Kiniksa Pharmaceuticals International's return on equity of 13.65% beat Stoke Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Stoke Therapeutics-753.60% -59.36% -51.46%
Kiniksa Pharmaceuticals International 9.59%13.65%10.09%

54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. 9.6% of Stoke Therapeutics shares are held by insiders. Comparatively, 52.0% of Kiniksa Pharmaceuticals International shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Kiniksa Pharmaceuticals International has higher revenue and earnings than Stoke Therapeutics. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Stoke Therapeutics$184.42M9.10-$6.89M-$3.34N/A
Kiniksa Pharmaceuticals International$677.56M8.71$59.01M$0.9777.97

Stoke Therapeutics has a beta of 1.26, meaning that its share price is 26% more volatile than the broader market. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.04, meaning that its share price is 96% less volatile than the broader market.

Summary

Kiniksa Pharmaceuticals International beats Stoke Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Stoke Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for STOK and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STOK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

STOK vs. The Competition

Export
MetricStoke TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.68B$3.83B$7.09B$13.24B
Dividend YieldN/A3.64%2.53%15.89%
P/E RatioN/A12.99274.6126.05
Price / Sales8.961,288.54600.5190.03
Price / CashN/A121.7677.3851.25
Price / Book4.1516.6310.926.31
Net Income-$6.89M-$22.67M$3.50B$361.43M
7 Day Performance3.31%-3.05%-2.11%-1.67%
1 Month Performance-16.00%-10.75%-6.34%-3.94%
1 Year Performance3.22%21.11%8.81%2.77%

Stoke Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
STOK
Stoke Therapeutics
3.0759 of 5 stars		$25.62
-1.5%		$44.25
+72.7%		+10.3%$1.68B$184.42MN/A170
ALKS
Alkermes
3.08 of 5 stars		$44.18
+1.8%		$54.56
+23.5%		+32.3%$7.28B$1.48B116.272,050
RYTM
Rhythm Pharmaceuticals
2.6882 of 5 stars		$98.83
+1.1%		$140.67
+42.3%		-6.6%$6.70B$189.76MN/A414
CGON
CG Oncology
2.3174 of 5 stars		$78.25
+4.9%		$87.78
+12.2%		+73.2%$6.61B$4.04MN/A142
ORKA
Oruka Therapeutics
2.2611 of 5 stars		$93.38
-1.7%		$133.00
+42.4%		+348.0%$6.29BN/AN/A68

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:STOK) was last updated on 10/2/2026 by MarketBeat.com Staff.
From Our Partners
Elon Warns "America Will Go Bankrupt". Trump's Plan Inside.
National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...
American Hartford Gold | Sponsoredtc pixel
How options let you do more with less capital
Would you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...
Base Camp Trading | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
WATCH THIS BEFORE DECEMBER 8th!!
James Altucher says a quiet government filing could reveal Elon Musk's biggest move yet, and almost nobody has...
Paradigm Press | Sponsoredtc pixel
A new kind of civil war is coming after election day?
Across America, AI-driven backlash is fueling protests, lawsuits, and moratoria that could reshape the politic...
Stansberry Research | Sponsoredtc pixel
How Elon’s Empire Ends (and how to profit)
Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...
Chaikin Analytics | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel